Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A targeted drug composition for treating liver cancer

A technology for treating liver cancer and a composition, applied in the field of biomedicine, can solve problems such as weakening the anti-angiogenesis effect of bevacizumab, and achieve the effects of inhibiting tumor growth, inhibiting tumor angiogenesis and improving therapeutic effect.

Inactive Publication Date: 2011-11-30
SHANGHAI FIRST PEOPLES HOSPITAL
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Preliminary research on the mechanism of this phenomenon found that low-dose bevacizumab in vivo can induce positive feedback in tumor tissue to enhance the expression of angiogenesis-promoting factors such as VEGF, thereby weakening the anti-angiogenic effect of bevacizumab

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A targeted drug composition for treating liver cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: MIT+bevacizumab combined inhibition of liver cancer angiogenesis and tumor growth

[0026] 1. Experimental animals: 8-week-old BALB / c nude mice provided by the Experimental Animal Center of Shanghai Branch of the Chinese Academy of Sciences

[0027] 2. Experimental materials: MIT, bevacizumab, low-metastatic human liver cancer cell lines, MHCC97-HG (CGMCC No: 1063) and MHCC97-LG (CGMCC No: 1062).

[0028] 3. Experimental method: using the above-mentioned liver cancer cell line, subcutaneous injection and orthotopic planting to establish animal models, and detecting the effect of different doses of NS / LgG scheme, MIT scheme, bevacizumab scheme and different dosage groups of the pharmaceutical composition of the present invention on inhibiting tumor tissue Angiogenesis and anti-tumor growth effects.

[0029] 4. Experimental results: bevacizumab (25 μg, 50 μg, 100 μg) produced dose-dependent inhibition of angiogenesis and anti-tumor growth, and MIT (0.1 mg / kg) ...

Embodiment 2

[0030] Example 2 Combined therapy of MIT+bevacizumab inhibits angiogenesis and tumor growth of pancreatic cancer

[0031] 1. Experimental animals: 8-week-old BALB / c nude mice provided by the Experimental Animal Center of the Shanghai Branch of the Chinese Academy of Sciences,

[0032] 2. Experimental materials: MIT, bevacizumab, pancreatic cancer cell lines PANC-1 and BxPC3,

[0033] 3. Experimental method: Using the above-mentioned pancreatic cancer cell lines, subcutaneous injection and orthotopic implantation to establish tumor-bearing animal models, testing different doses of NS / LgG regimens, MIT regimens, bevacizumab regimens, and different dose combinations of MIT+bevacizumab combined with new chemotherapy regimens Effects of four chemotherapy regimens on inhibiting tumor angiogenesis and anti-tumor growth.

[0034]4. Experimental results: When chemotherapy was performed when the tumor reached the size required by the experiment, bevacizumab (25 μg, 50 μg, 100 μg) produ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine and relates to a targeted drug for treating tumors in biomedicine, in particular to a targeted drug composition for treating liver cancer. The targeted pharmaceutical composition of the present invention includes a low dose of 0.10 mg / kg / time shimmering mycin MIT and 25 μg / time anti-VEGF antibody drug; the present invention has carried out in vivo liver cancer, gastric cancer, pancreatic cancer tumor-bearing nude mouse model experiments, observed Effects on tumor angiogenesis and the cytokines that regulate its production. The results show that MIT alone in a lower safe dose range can neither affect the normal physiological activities of experimental animals nor inhibit liver tumor angiogenesis and growth or only have a weak effect; but when given the pharmaceutical composition of the present invention, It can inhibit tumor angiogenesis, and then inhibit the growth of liver tumors without increasing drug toxicity.

Description

technical field [0001] The invention belongs to the field of biomedicine and relates to a targeted drug for treating tumors in biomedicine, in particular to a targeted drug composition for treating liver cancer. Background technique [0002] Clinical research shows that the morbidity and mortality of malignant tumors are increasing year by year, and it has become a major disease that seriously affects people's health. At present, tumor therapy has entered the era of molecular targeting. Theoretically speaking, the anti-angiogenesis treatment strategy that targets and inhibits tumor supply blood vessels has the characteristics of broad anti-tumor spectrum, less resistance to drugs, and easy access of drugs to target sites, which has become a hot research topic in tumor biotherapy. Tumor angiogenesis is a complex process involving multiple cell proliferation, apoptosis, and extracellular matrix degradation and remodeling. Among them, the transcription factor SP1 in tumor cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P35/00A61K31/704
Inventor 王理伟
Owner SHANGHAI FIRST PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com